Brief: Pmv Pharmaceuticals Reports Third Quarter Results
08/11/2022 14:33
Nov 8 (Reuters) - Pmv Pharmaceuticals Inc PMVP.O :
* PMV PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND CORPORATE HIGHLIGHTS
* PHASE 1B COMBINATION TRIAL WITH MERCK EVALUATING PC14586
WITH
KEYTRUDA(®) (PEMBROLIZUMAB) ON TRACK TO INITIATE IN 2022
* QTRLY LOSS PER SHARE $0.40
* Q3 EARNINGS PER SHARE VIEW $-0.42 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4Zsb7N
Further company coverage: PMVP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Pmv Pharmaceuticals
See all newsAustralia's Premier Investments jumps as Citi backs in-line earnings
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics